Table 2. Grade 2, 3 and 4 adverse events following treatment with capecitabine in 25 patients and 88 treatment cycles.

Toxicity	Grade	Number of cycles (% of cycles)	Number of patients (% of patients)
Anaemia	2	17 (19%)	9 (36%)
	3	1 (1%)	1 (4%)
Leukopenia	2	4 (5%)	2 (8%)
	3	1 (1%)	1 (4%)
Granulocytopenia	2	1 (1%)	1 (4%)
	3	2 (2%)	2 (8%)
Thrombocytopenia	2	2 (2%)	2 (8%)
Diarrhoea	2	4 (5%)	3 (12%)
	3	1 (1%)	1 (4%)
Neurological	2	4 (5%)	3 (12%)
Nausea	2	10 (11%)	6 (24%)
	3	2 (2%)	2 (8%)
Stomatitis	2	1 (1%)	1 (4%)
	4	1 (1%)	1 (4%)
Hand–foot syndrome	2	9 (10%)	4 (16%)
	3	5 (6%)	4 (16%)